Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Next Previous
Trial Profile

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTP 100 (Primary)
  • Indications Influenza A virus H3N2 subtype
  • Focus Pharmacodynamics
  • Sponsors Barinthus Biotherapeutics; Vaccitech

Most Recent Events

  • 31 Jan 2020 According to the Vaccitech media release, the company will continue its obligations under the contract with BARDA to analyse potential immunological correlates associated with protection or risk from disease. The trial was conducted under review by both the FDA and the Belgian Regulatory Authority, FAMHP.
  • 31 Jan 2020 Primary endpoint has not been met. (Degree of viral shedding), according to an Vaccitech media release.
  • 31 Jan 2020 Results published in the Vaccitech Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top